Amit M Oza
University Health Network, Toronto · UHN - Princess Margaret Cancer Centre · University Health Network-Princess Margaret Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amit M Oza as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04574765 · A Research Platform to Screen Healthcare Workers- Coordinated Approach to Pandemic Trials of COVID-19University Health Network, Toronto · completed · Healthcare Worker, Covid19 · principal investigator
- Ph2NCT03016338 · Study of Niraparib and TSR-042 in Recurrent Endometrial CancerUniversity Health Network, Toronto · active not recruiting · Endometrial Cancer · study director
- Ph2NCT02101775 · Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI) · active not recruiting · Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma · principal investigator
- Ph2NCT01693783 · Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerNational Cancer Institute (NCI) · completed · Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection · principal investigator
- Ph2NCT00770185 · Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial CancerNCIC Clinical Trials Group · completed · Endometrial Cancer · study chair
- Ph2NCT00478426 · Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma · principal investigator
- Ph2NCT00003892 · ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian CancerNCIC Clinical Trials Group · completed · Ovarian Cancer · study chair
- Ph2NCT00052507 · Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal CancerUniversity Health Network, Toronto · completed · Colorectal Cancer · study chair
- Ph2NCT00030485 · Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Princess Margaret Phase I Consorium (PMP1C)UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2016 to 2019 · $99,360 awarded in 2019Grant number is on one of their registry trials
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS26120110003 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2011 to 2015 · $1,116,421 awarded in 2015Same name and institution; not confirmed by an ID
- Early Therapeutics Development with Phase II EmphasisN01CM62203- · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2007 to 2011 · $693,681 awarded in 2011Grant number is on one of their registry trials
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622003N01CM622003 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT02101775, NCT01693783
- Experimental Therapeutics: Clinical Trials Network with Phase I EmphasisUM1CA186705 · NCI · UNIVERSITY OF CHICAGO · PI Michael L. Maitland, MARK J RATAIN, WALTER M. STADLER · fiscal years 2014 to 2015Named on NCT02101775, NCT01693783
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 122 PubMed records, and a shared surname and initials can bring in a namesake. All 122 on PubMed
- 2,017 citationsRCR 64.0
- A phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med · 20111,749 citationsRCR 45.0
- 1,432 citationsRCR 46.8
- 1,419 citationsRCR 44.3
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol · 2017974 citationsRCR 29.9
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol · 2015683 citationsRCR 21.5
- 540 citationsRCR 13.1
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Lancet Oncol · 2015451 citationsRCR 12.4
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol · 2019437 citationsRCR 14.6
- 432 citationsRCR 9.9